CSR - Protalix BioTherapeutics GAAP EPS of -$0.11 beats by $0.07 revenue of $8.75M beats by $6.08M

• Protalix BioTherapeutics press release ( NYSE: PLX ): Q2 GAAP EPS of -$0.11 beats by $0.07 .
• Revenue of $8.75M (+36.1% Y/Y) beats by $6.08M .
• "Positive topline results from our phase III BALANCE clinical trial of PRX-102 for the treatment of adult patients with Fabry disease were announced last April. The clinical study report ( CSR ) for the trial is now complete," said Dror Bashan, Protalix's President and Chief Executive Officer. "The final analysis of the BALANCE study, which was designed to evaluate the efficacy and safety of 1 mg/kg of PRX–102 administered every other week compared to agalsidase beta in patients previously treated with agalsidase beta, confirms the positive topline results and favorable tolerability profile. The results from the BALANCE study highlight our confidence that PRX–102 has the potential to become an important treatment option for patients with Fabry disease. We are excited to move closer to potential approval of PRX–102 and commercial launch, and thank our team members and external partners for their continued support."

For further details see: